TRVI
Trevi Therapeutics, Inc.
Biotechnology · Healthcare · United States
13.56
close · 2026-10-30
value
98
cheaper than peers98
quality
96
stronger fundamentals96
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| earnings yield, 2 years ago | -2.1% | 97 |
| earnings yield, latest year | -2.4% | 96 |
| cash flow yield, latest year | -2.2% | 93 |
| cash flow yield, 2 years ago | -1.6% | 93 |
| earnings yield, 3 years ago | -3.3% | 93 |
| cash flow yield, 1 year ago | -2.0% | 91 |
| earnings yield, 1 year ago | -3.5% | 91 |
| cash flow yield, 3 years ago | -1.5% | 87 |
| price to book | 6.01× | 23 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | -19.7% | 95 |
| debt to equity | 0.2% | 93 |
| operating margin | 0.0% | 50 |
3 of 4 measures available
Facts
| market cap | $2B |
| free cash flow | -$33.3M |
| employees | 34 |
| first trade | 2019-05-07 |
| next earnings | 2026-08-06 |
| fundamentals updated | 2026-08-10 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 | 2021 |
| diluted eps | -0.32 | -0.47 | -0.29 | -0.45 | not reported |
| free cash flow | -$42.1M | -$38.3M | -$31.8M | -$28.3M | not reported |
| net income | -$42.8M | -$47.9M | -$29.1M | -$29.2M | not reported |
| revenue | $0 | $0 | $0 | $0 | not reported |
| unusual items | not reported | not reported | not reported | -$147,000 | $82,000 |